NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ZYME Stock Alerts $9.20 +0.20 (+2.22%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$8.53▼$9.2450-Day Range$8.11▼$12.9052-Week Range$6.01▼$13.14Volume655,723 shsAverage Volume587,403 shsMarket Capitalization$649.24 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Zymeworks alerts: Email Address Zymeworks MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside49.5% Upside$13.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector4627th out of 5,430 stocksPharmaceutical Preparations Industry2167th out of 2,526 stocks 3.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 1.6 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Zymeworks this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($1.04) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Zymeworks: Anticipated Approvals and Strong Pipeline PotentialMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks on Strong Pipeline and Upcoming CatalystsMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 3, 2024 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comZymeworks Inc (ZYME) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...April 30, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 25, 2024 | americanbankingnews.comZymeworks (ZYME) Scheduled to Post Quarterly Earnings on ThursdayMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 18, 2024 | seekingalpha.comBuy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising DataApril 16, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud AllegationsApril 12, 2024 | markets.businessinsider.comMaintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory HurdlesApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 11, 2024 | globenewswire.comZymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024April 8, 2024 | globenewswire.comZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual MeetingApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 4, 2024 | morningstar.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)April 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEMarch 28, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 28, 2024 | globenewswire.comZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 27, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of ZanidatamabMarch 11, 2024 | markets.businessinsider.comHold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation AwaitedMarch 8, 2024 | investorplace.comNext-Gen Winners: 7 Tech Stocks Set to Dominate the DecadeMarch 7, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/03/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees272Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+63.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-156.12% Pretax Margin-156.87% Return on Equity-26.20% Return on Assets-20.29% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$76.01 million Price / Sales8.54 Cash FlowN/A Price / Cash FlowN/A Book Value$6.63 per share Price / Book1.39Miscellaneous Outstanding Shares70,570,000Free Float69,707,000Market Cap$649.24 million OptionableOptionable Beta1.16 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)CEO & Chairman of the Board Comp: $1.04MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $682.22kDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Comp: $872.67kMr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorVice President of Human Resources & DEIDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia PacificMore ExecutivesKey CompetitorsMineralys TherapeuticsNASDAQ:MLYSWave Life SciencesNASDAQ:WVEORIC PharmaceuticalsNASDAQ:ORICNurix TherapeuticsNASDAQ:NRIXCogent BiosciencesNASDAQ:COGTView All CompetitorsInsiders & InstitutionsPrincipal Financial Group Inc.Bought 25,971 shares on 4/29/2024Ownership: 0.037%China Universal Asset Management Co. Ltd.Bought 5,344 shares on 4/29/2024Ownership: 0.019%Assenagon Asset Management S.A.Bought 166,549 shares on 4/24/2024Ownership: 0.236%Allspring Global Investments Holdings LLCSold 84,410 shares on 4/18/2024Ownership: 0.203%AlphaMark Advisors LLCBought 3,004 shares on 4/18/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZYME shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price target for 2024? 3 analysts have issued 12-month target prices for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's share price to reach $13.75 in the next twelve months. This suggests a possible upside of 49.5% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2024? Zymeworks' stock was trading at $10.39 at the start of the year. Since then, ZYME shares have decreased by 11.5% and is now trading at $9.20. View the best growth stocks for 2024 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.19. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative trailing twelve-month return on equity of 26.20%. What ETF holds Zymeworks' stock? Invesco Russell 2000 Dynamic Multifactor ETF holds 158,988 shares of ZYME stock, representing 0.37% of its portfolio. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.24%), Allspring Global Investments Holdings LLC (0.20%), Principal Financial Group Inc. (0.04%), China Universal Asset Management Co. Ltd. (0.02%) and AlphaMark Advisors LLC (0.00%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ZYME) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
